References
- Dauignon J Bouthillier D . Probucol and familial hypercholesterolemia. Can. Med. Assoc. J.126 (9), 1024–1025 (1982).
- Zhou Z Chen S Zhao H et al. Probucol inhibits neural cell apoptosis via inhibition of mTOR signaling pathway after spinal cord injury. Neuroscience329193–329200 (2016).
- Ribeiro RP Moreira EL Santos DB et al. Probucol affords neuroprotection in a 6-OHDA mouse model of Parkinson's disease. Neurochem. Res.38 (3), 660–668 (2013).
- Santos DB Peres KC Ribeiro RP et al. Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid beta peptide in mice. Exp. Neurol.233 (2), 767–775 (2012).
- Nielsen FS Petersen KB Mullertz A . Bioavailability of probucol from lipid and surfactant based formulations in minipigs: influence of droplet size and dietary state. Eur. J. Pharm. Biopharm.69 (2), 553–562 (2008).
- Lam V Hackett M Takechi R . Antioxidants and dementia risk: consideration through a cerebrovascular perspective. Nutrients8 (12), (2016).
- Fakhoury M Takechi R Al-Salami H . Drug permeation across the blood–brain barrier: applications of nanotechnology. Br. J. Med. Med. Res.6 (6), 547–556 (2014).
- Mooranian A Negrulj R Takechi R et al. The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects. Drug Deliv. Transl. Res.8 (3), 543–551 (2018).
- Al-Salami H Mamo JC Mooranian A et al. Long-term supplementation of microencapsulated ursodeoxycholic acid prevents hypertension in a mouse model of insulin resistance. Exp. Clin. Endocrinol. Diabetes125 (1), 28–32 (2017).
- Mooranian A Negrulj R Takechi R et al. The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects. Drug Deliv. Transl. Res.8 (3), 543–551 (2018).
- Nagpal M Maheshwari D Rakha P et al. Formulation development and evaluation of alginate microspheres of Ibuprofen. J. Young Pharm.4 (1), 13–16 (2012).
- Gulyaev AE Gelperina SE Skidan IN et al. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res.16 (10), 1564–1569 (1999).
- Juillerat-Jeanneret L . The targeted delivery of cancer drugs across the blood–brain barrier: chemical modifications of drugs or drug-nanoparticles?Drug Discov. Today13 (23–24), 1099–1106 (2008).
- Kesaniemi YA Grundy SM . Influence of probucol on cholesterol and lipoprotein metabolism in man. J. Lipid Res.25 (8), 780–790 (1984).
- Takechi R Galloway S Pallebage-Gamarallage MM Lam V Mamo JC . Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk. Prog. Lipid Res.49 (2), 159–170 (2010).
- Takechi R Pallebage-Gamarallage MM Lam V Giles C Mamo JC . Aging-related changes in blood–brain barrier integrity and the effect of dietary fat. Neurodegener. Dis.12 (3), 125–135 (2013).
- Takechi R Lam V Brook E et al. Blood–brain barrier dysfunction precedes cognitive decline and neurodegeneration in diabetic insulin resistant mouse model: an implication for causal link. Front. Aging Neurosci.9399 (2017).